Drug intelligence / Profile preview

EBT-002

Development stage: Preclinical
Lead developer: Ernest Pharmaceuticals
Modality: Drug Delivery Systems
Administration: Intravenous

Overview

EBT-002 is a preclinical biological therapeutic developed by Ernest Pharmaceuticals for the treatment of advanced solid tumors, such as liver cancer. It utilizes the company's proprietary Bacterial Intracellular Delivery (BacID) vector platform. This bacterial therapy is designed to specifically target tumor cells and deliver a biological payload that activates caspase-3, an key enzyme in the apoptotic (cell death) pathway. The intended mechanism is to induce apoptosis in cancer cells while minimizing damage to healthy tissues. The drug is currently in the IND-enabling phase of development.

Targets

CASP3 (Caspase-3)

Beyond the preview

Go deeper on EBT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBT-002.

Explore the full profile